Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
This study compared the activity of cefepime + zidebactam (FEP-ZID) and selected currently available antibacterial agents against a panel of multidrug-resistant (MDR) clinical isolates chosen to provide an extreme challenge for antibacterial activity. FEP–ZID had a very broad and potent in...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-03-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/8/1/32 |
| _version_ | 1818057549720584192 |
|---|---|
| author | Kenneth S. Thomson Sameh AbdelGhani James W. Snyder Gina K. Thomson |
| author_facet | Kenneth S. Thomson Sameh AbdelGhani James W. Snyder Gina K. Thomson |
| author_sort | Kenneth S. Thomson |
| collection | DOAJ |
| description | This study compared the activity of cefepime + zidebactam (FEP-ZID) and selected currently available antibacterial agents against a panel of multidrug-resistant (MDR) clinical isolates chosen to provide an extreme challenge for antibacterial activity. FEP–ZID had a very broad and potent in vitro spectrum of activity, and was highly active against many MDR isolates of <i>Enterobacterales</i>, <i>Pseudomonas aeruginosa</i>, and <i>Acinetobacter baumannii</i>. Notably, it inhibited isolates producing carbapenemases of Ambler classes A, B, and D, and <i>P. aeruginosa</i> isolates with multiple resistance mechanisms including combinations of upregulated efflux, diminished or non-functional OprD porins, and AmpC overproduction. Its clinical role will be determined initially by the breakpoints assigned to it, comparison studies with other investigational β-lactamase inhibitor combinations, and ultimately by the developing body of therapeutic outcome data. |
| first_indexed | 2024-12-10T12:46:30Z |
| format | Article |
| id | doaj.art-412700892c884114b096feba3b20d2c5 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-12-10T12:46:30Z |
| publishDate | 2019-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-412700892c884114b096feba3b20d2c52022-12-22T01:48:23ZengMDPI AGAntibiotics2079-63822019-03-01813210.3390/antibiotics8010032antibiotics8010032Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative PathogensKenneth S. Thomson0Sameh AbdelGhani1James W. Snyder2Gina K. Thomson3Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USADepartment of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USADepartment of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USADepartment of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USAThis study compared the activity of cefepime + zidebactam (FEP-ZID) and selected currently available antibacterial agents against a panel of multidrug-resistant (MDR) clinical isolates chosen to provide an extreme challenge for antibacterial activity. FEP–ZID had a very broad and potent in vitro spectrum of activity, and was highly active against many MDR isolates of <i>Enterobacterales</i>, <i>Pseudomonas aeruginosa</i>, and <i>Acinetobacter baumannii</i>. Notably, it inhibited isolates producing carbapenemases of Ambler classes A, B, and D, and <i>P. aeruginosa</i> isolates with multiple resistance mechanisms including combinations of upregulated efflux, diminished or non-functional OprD porins, and AmpC overproduction. Its clinical role will be determined initially by the breakpoints assigned to it, comparison studies with other investigational β-lactamase inhibitor combinations, and ultimately by the developing body of therapeutic outcome data.https://www.mdpi.com/2079-6382/8/1/32carbapenemase-producing organismcarbapenemasezidebactamtherapy |
| spellingShingle | Kenneth S. Thomson Sameh AbdelGhani James W. Snyder Gina K. Thomson Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens Antibiotics carbapenemase-producing organism carbapenemase zidebactam therapy |
| title | Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens |
| title_full | Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens |
| title_fullStr | Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens |
| title_full_unstemmed | Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens |
| title_short | Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens |
| title_sort | activity of cefepime zidebactam against multidrug resistant mdr gram negative pathogens |
| topic | carbapenemase-producing organism carbapenemase zidebactam therapy |
| url | https://www.mdpi.com/2079-6382/8/1/32 |
| work_keys_str_mv | AT kennethsthomson activityofcefepimezidebactamagainstmultidrugresistantmdrgramnegativepathogens AT samehabdelghani activityofcefepimezidebactamagainstmultidrugresistantmdrgramnegativepathogens AT jameswsnyder activityofcefepimezidebactamagainstmultidrugresistantmdrgramnegativepathogens AT ginakthomson activityofcefepimezidebactamagainstmultidrugresistantmdrgramnegativepathogens |